Indeed, a prospective assessment of the association between the overexpression of TCN1/TCN2/CD320 or high loads of TCI/TCII/TCII-R on immunohistological analyses of cancer tissues and their resistance to treatment, or for the prognosis, will help to adapt the treatment and survey strategy. The gene discussed is CD320; the disease is cancer.